A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group.
A European Malignant Hyperpyrexia Group has been formed to facilitate exchange of information between centres performing in vitro muscle testing for malignant hyperpyrexia susceptibility. Data have been collected according to a protocol agreed by the Group. Based on these results, test criteria have been established to allow the following diagnoses to be made: MH susceptible (MHS); MH normal (MHN) or MH equivocal (MHE). It is accepted that MHE classified patients will be under permanent review, pending the collection of further data.
D001706:Biopsy; D002110:Caffeine / Q000494:pharmacology; D004198:Disease Susceptibility; D005820:Genetic Testing; D006221:Halothane / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D008305:Malignant Hyperthermia / Q000175:diagnosis* / Q000517:prevention & control; D008722:Methods; D009119:Muscle Contraction / Q000187:drug effects; D009132:Muscles / Q000473:pathology
D002110:Caffeine; D006221:Halothane